Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FFAR4 | Q5NUL3 | 4/20 | 0.34 |
| ▸ | CYP2C9 | P11712 | 6/20 | 0.34 |
| ▸ | MOGAT2 | Q3SYC2 | 6/20 | 0.34 |
| ▸ | NAAA | Q02083 | 4/20 | 0.32 |
| ▸ | ALDH2 | P05091 | 1/20 | 0.32 |
| ▸ | MAOA | P21397 | 1/20 | 0.32 |
| ▸ | MAOB | P27338 | 1/20 | 0.32 |
| ▸ | HTR6 | P50406 | 1/20 | 0.31 |
| ▸ | FFAR1 | O14842 | 3/20 | 0.31 |
| ▸ | ALOX5AP | P20292 | 2/20 | 0.31 |
| ▸ | FEN1 | P39748 | 2/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12740371 | 0.96 | CYP2C9 (0.34) | FFAR4CYP2C9MOGAT2NAAAHTR6 | |
| SCHEMBL14766732 | 0.93 | FFAR4 (0.34) | FFAR4NAAAALDH2MAOAMAOB | |
| SCHEMBL12736861 | 0.93 | FFAR4 (0.34) | FFAR4CYP2C9MOGAT2ALDH2MAOA | |
| SCHEMBL12740370 | 0.91 | FFAR4 (0.34) | FFAR4NAAAALDH2MAOAMAOB | |
| SCHEMBL12740364 | 0.91 | FFAR4 (0.36) | FFAR4CYP2C9MOGAT2NAAAFFAR1 | |
| SCHEMBL14767254 | 0.90 | FFAR4 (0.34) | FFAR4NAAAFFAR1ALOX5APFEN1 | |
| SCHEMBL12733968 | 0.90 | FFAR4 (0.35) | FFAR4CYP2C9MOGAT2ALDH2MAOA | |
| SCHEMBL14766870 | 0.90 | FFAR4 (0.35) | FFAR4NAAAFFAR1ALOX5APFEN1 | |
| SCHEMBL12736858 | 0.90 | FFAR4 (0.33) | FFAR4CYP2C9MOGAT2FFAR1ALOX5AP | |
| SCHEMBL12740365 | 0.89 | FFAR4 (0.35) | FFAR4CYP2C9MOGAT2NAAAFFAR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8394294-B2 | Four-ring liquid crystal compound having lateral fluorine, liquid crystal composition and liquid crystal display device | JNC CORPORATION (JP) | 2013-03-12 | — | — | US | disclosed |
| US-20110090450-A1 | FOUR-RING LIQUID CRYSTAL COMPOUND HAVING LATERAL FLUORINE, LIQUID CRYSTAL COMPOSITION AND LIQUID CRYSTAL DISPLAY DEVICE | JNC CORPORATION (JP) | 2011-04-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110090450-A1 | FOUR-RING LIQUID CRYSTAL COMPOUND HAVING LATERAL FLUORINE, LIQUID CRYSTAL COMPOSITION AND LIQUID CRYSTAL DISPLAY DEVICE | LEF1, LAS1L, EFHD2 | FFAR4 546/4885CYP2C9 2816/4885MOGAT2 992/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.